follow-up of 13.5 months, half of the patients had no evidence of disease.

**Conclusion** Our institutional experience comprising intensive clinical and emotional management of vulvar carcinoma radiotherapy provides a proactive approach involving frequent assessment, initiated breaks and emotional support, all facilitating improvement in historically low treatment compliance.

### 2022-RA-1163-ESGO

**METASTATIC ADENOID CYSTIC CARCINOMA GLAND BARTHOLINI: A CASE REPORT**


**Introduction/Background** Adenocarcinoma gland Bartholin’s is a very rare tumor accounting for 2–7% of all cancers of the vulva and less than 1% of all female genital malignancies. These tumors’ basic features are slow growth, expanding locally, and sometimes this tumor expanding as metastatic from the other organs like carcinoma mamma. There is no agreement on optimal treatment for this type of carcinoma.

**Methodology** We will show the case 64-year-old woman who came to our hospital because of a tumor mass in the region gland Bartholin’s. She already had the operation because of Carcinoma mamma ten years ago. A gynecological examination can be seen enlarged Bartholin’s gland about 5 cm in diameter to the left side. The other gynecological examination was normal.

**Results** We performed a local-wide removal of the tumor. Histopathology confirmed that this is metastatic Bartholin’s gland adenocarcinoma. The tumor was removed in its entirety with a healthy edge. CT and MRI of the pelvis were normal. We decided to follow up patient but after six months she had recurrences of the disease. We treated her by local irradiation but the patient, unfortunately, died after one year after.

**Conclusion** This case indicates that meta changes could be fined even on unusual localization like in our case. Follow-up patients with carcinoma must include an examination of the whole body and every change should be treated immediately.

### 2022-RA-1165-ESGO

**FEASIBILITY AND SAFETY OF INGUINOEMORAL SENTINEL LYMPH NODE BIOPSY FOR PREVIOUSLY EXCISED VULVAR CANCER**

1. Erica Pascoal, 2. Mohammad Alyafi, 3. Alda Pokoradi, 3. Lura Eiksson, 3. Limor Helfman, 1. Obstetrics and Gynecology, McMaster University, Hamilton, ON, Canada; 2. GyneOncology Oncology, King Abdulaziz University, Jeddah, Saudi Arabia; 3. GyneOncology Oncology, McMaster University, Hamilton, ON, Canada; 4. GyneOncology Oncology, Tel Aviv University, Tel Aviv, Israel

**Introduction/Background** Performing inguinofemoral sentinel lymph node biopsy (IFSLNB) for vulvar cancer following a previous vulvar excision, often referred to as ‘scar injection,’ is currently debated. Our study aimed to assess the feasibility and safety of IFSLNB following scar injection.

**Methodology** We conducted a retrospective observational study of patients with vulvar cancer, who underwent IFSLNB following radiotracer injection around a tumour or around a scar following previous vulvar excision. IFSLN detection rates are described per patient and per groin and are compared using chi-square analysis. We performed a Cox regression analysis to assess the association of recurrence and survival with vulvar injection site and recognized pathological variables.

**Results** Data was analyzed for 173 groins in 97 patients. At least one IFSLN was detected in 94% of groins examined, and IFSLN detection rate did not differ whether the groin was assessed following tumour injection (n=122, 94%) or scar injection (n=40, 93%; p=0.85). Patients in the scar injection group had less frequent IFLN metastases (p=0.019), smaller tumours (p<0.001) and more superficial invasion (p<0.02). Median overall follow-up from surgery to death or censoring was 34.7 (range 0–108) months. Cox regression analysis demonstrated that scar injection was not an independent predictor of recurrence or death, and depth of invasion was the only independent predictor of disease recurrence (HR 1.14, p=0.029).

**Conclusion** Our observations support the feasibility and safety of scar injection as an alternative to full lymphadenectomy and should be validated in a prospective study with a more robust sample size.

### 2022-RA-1171-ESGO

**TOTAL VAGINECTOMY FOR RECURRENT GYNECOLOGICAL CANCER. EXPERIENCE IN KAZIOR**


**Introduction/Background** The strategy for the treatment of vaginal recurrence of gynecological cancer remains a complex clinical problem. Surgery is an effective and relatively safe strategy for these cases. Vaginectomy is one of the methods of surgical treatment of local recurrence of gynecological cancer. Although vaginectomy is considered an effective treatment for vaginal recurrence of cervical, ovarian, and endometrial cancers, only a few published reports of vaginal resections have been found, and in most cases vaginal resections have been performed by vaginal and/or open access. Several reports of laparoscopic vaginal resection for recurrence in gynecological cancer have also been found.

**Methodology** 7 patients were studied after vaginectomy.

**Results** The age of the patients ranged from 42 to 62 years (median 53 years). The duration of the operation varied from 240 to 480 minutes (median 317 min), the volume of blood loss ranged from 90 to 220 ml (median 140 ml), resection margins were negative in all cases. In 2 patients, a ureteral catheter was placed. The Foley catheter was removed after a median of 10 days (range 1 to 11 days). The length of stay of patients in the hospital ranged from 7 to 14 days (median 7 days). There were no intraoperative complications. All patients after vaginectomy are alive.

**Conclusion** Vaginal recurrence is the most common type of local recurrence in gynecological cancer, and there is no consensus on treatment tactics. This article is somewhat limited in